Sheet <u>1</u> of <u>2</u>

	TIPERS	
PAT	AUG 0 3 2007 \$	
(E)	PADEMARKORES	
	TUEMAN	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	. ATTY. DOCKET NO 1038-1129 MIS:ac	SERIAL NO. 09/786,235
	RMATION DISCLOSURE TEMENT BY APPLICANT		
		APPLICANT Diane M. Gajewczyk et al	
		FILING DATE September 3, 1999	GROUP

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
A	6,004,557	Dec. 1999	Edwards et al.		-	
	6.013.258	Jan. 2000	Urban et al.			
V	5,744,133	April 1998	Lathe et al.			

FOREIGN PATENT DOCUMENTS

	T	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANS	LATION
AS	 	WO 96/00583	Jan. 11/96				YES	NO
	<u> </u>	WO 92/16636	Oct. 1/92					
		WO 97/05164	Feb. 13/97	-				
		WO 99/18995	Apr. 22/99		_			
V		WO 93/24640	Dec. 9/93		_			
-	4.	OTHER DOCUM	MENTS (Includin	g Author, Title, Date, Pe	rtinent Pa	ges, Etc.)	·	
A)	**	1. Pisani P. et al. Cancer 1993 :		e worldwide mortality from	eighteen r	najor cance	rs in 1985.	int. J.
	**	2. Piver M.S., Ha	ndbood of gynec	ologic oncology. Boston:	Little, Brow	n, 1996.		
	**	Kurman R.J. et al., Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop, IAMA 1994-271: 1866-9.						
	**	Bosch FX, et al., Prevalence of hman papillomavirus in cervical cancer a worlwide perspective. J. National Cancer Institute. 1995:87:796-802.						
	**	5. Pecoraso G. et al., Differential effects of human papillomavires type 6, 16 and 18 DNAs USA, 1989: 86, pp. 563-567.						
	**	Shamanin C.G., et al., Specific types of human papilllomavirus found in bening preliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 1994:54, pp. 4610-3.						
	**	7. Hilders C.G., et al., Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Laboratories Investigation. 1993: 69, pp.651-619.						
	**	Munger K., et al., Interactions of HPV E6 and E7 oncoproteins with tumour suppresssor gene products. Cancer Surv. 1992:12, pp. 197-217.						
	**	9. Dyson N., et al 1989:243, pp.9	., The human pa 34-937.	pilloma virus-16 E7 oncop	proteins wit	h tumour	Science :	
V	**	10. Munger K., et	al., Virol 1989 : 6	63, pp. 4417-4421.				

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	. ATTY. DOCKET NO 1038-1129 MIS:ac	SERIAL NO. 09/786,235
INFO	DRMATION DISCLOSURE TEMENT BY APPLICANT		
•	<u>k)</u>	APPLICANT Diane M. Gajewczyk et al	
AUG 0 3 ZOOT	l	FILING DATE September 3, 1999	GROUP

AS		11. Crook t., et al., Journal 1989 : 8, pp. 513-519
		12. Ressing M.E., et al,. J. Immunol. 1995:154, pp. 5934-5943, XP002915422
	**	13. Kast W.M., et al., J., Immunol. 1994:152, pp. 3904-3912.
		14. Feltkamp M.C., et al., Immunol. 1993:23, pp. 2242-2249.
	**	15. Alexander M., et al., J. Obster. Gynecol 1996:175, pp. 1586-1593.
	**	16. Steller M.A., et al., Human Papillomavirus immuology and vaccine prospects.J. Natl. Cancer Inst. Monogr. 1996:21, pp. 145-148.
	**	17. Schiller J.T., et al., Papillomavirus vaccines: Current status and future prospects. Adv. Dermatol 1996:11, ppl355-80; discussion: 355-80; discussion:381.
	••	18. Kimbauer R., et al., J. Virol 1993:67, pp. 6929-6936.
		19. Borysiewicz L.K. et al., Lancet 1996:347, pp. 1523-1527.
	**	20. Irvine K.R., et al., J. Immunol. 1995:154, pp. 4651-4657.
	-	21. WO 93/24640 duPlicate
		22. Tang et al., Nature 1992, 356: pp. 152-154.
		23. Furth et al., Analytical Biochemistry, 1992, 205, pp. 365-368.
		24. Munger K. et al., The EMBO Journal , 1989, vol. 8: 13, pp. 4099-4105. XP000611714.
		25. Sundaram P., et al., Vaccine 1998 : vol. 16, : 6, pp. 613-623. XPO002131646.
		·
	-	
<u> </u>	1	
	 	
EXAMINE	 R:	DATE CONSIDERED: 8/11/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

** Will follow shortly